High-fidelity AaCas12b(Max) enables the development of an engineered T cell therapy with enhanced safety and functional fitness.
- DOI
- 10.1016/j.ymthe.2025.09.009
- Published
- 2025 Dec 3
- Container
- Molecular therapy : the journal of the American Society of Gene Therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ymthe.2025.09.009,
title = {High-fidelity AaCas12b(Max) enables the development of an engineered T cell therapy with enhanced safety and functional fitness.},
author = {Sun J and Liu K and Sheng Y and Zhang H and Wang J and Wang Y and Tian R and Zhu X and Tian SS and Wang P and Zhao X and Liu Y},
year = {2025},
journal = {Molecular therapy : the journal of the American Society of Gene Therapy},
doi = {10.1016/j.ymthe.2025.09.009},
url = {https://doi.org/10.1016/j.ymthe.2025.09.009}
}RIS
TY - JOUR TI - High-fidelity AaCas12b(Max) enables the development of an engineered T cell therapy with enhanced safety and functional fitness. AU - Sun J AU - Liu K AU - Sheng Y AU - Zhang H AU - Wang J AU - Wang Y AU - Tian R AU - Zhu X AU - Tian SS AU - Wang P AU - Zhao X AU - Liu Y PY - 2025 JO - Molecular therapy : the journal of the American Society of Gene Therapy DO - 10.1016/j.ymthe.2025.09.009 UR - https://doi.org/10.1016/j.ymthe.2025.09.009 ER -
APA
J, S., K, L., Y, S., H, Z., J, W., Y, W., R, T., X, Z., SS, T., P, W., X, Z., & Y, L. (2025). High-fidelity AaCas12b(Max) enables the development of an engineered T cell therapy with enhanced safety and functional fitness.. Molecular therapy : the journal of the American Society of Gene Therapy. https://doi.org/10.1016/j.ymthe.2025.09.009
Source records
- pubmed · retrieved 2026-09-26T07:09:07.971Z